Physician profile
Imo A Ebong
NPI 1699932707
$65,370.37
in general payments reported to CMS, 2019-2025
18 companies · $52K in 2025
The $52K reported for 2025 was more than what 93% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,526 · 2020: $2,438 · 2021: $3,166 · 2022: $813 · 2023: $318 · 2024: $4,533 · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $55K · Food and Beverage: $1,103 · Travel and Lodging: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $55,180.00 |
| Food and Beverage | $1,103.08 |
| Travel and Lodging | $144.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $51,400.00 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $7,584.20 | 2019-2025 | Amvuttra, Onpattro |
| Akcea Therapeutics, INC. | $2,275.00 | 2020 | |
| Abbott Laboratories | $2,057.61 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $462.37 | 2019-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $331.20 | 2019-2023 | Lifevest |
| Medtronic Vascular, INC. | $288.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $271.98 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $140.52 | 2022-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $139.71 | 2022-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.03 | 2025 | |
| Pfizer INC. | $81.49 | 2022 | |
| Scpharmaceuticals INC. | $75.43 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $58.72 | 2020-2025 | |
| Boston Scientific Corporation | $56.82 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.63 | 2024 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imo Ebong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.